- Home
- FOA vs CLLS Comparison
FOA vs CLLS Comparison
Compare FOA & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- CLLS
- Stock Information
- Founded
- FOA 2013
- CLLS 1999
- Country
- FOA United States
- CLLS France
- Employees
- FOA N/A
- CLLS N/A
- Industry
- FOA Finance Companies
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- CLLS Health Care
- Exchange
- FOA Nasdaq
- CLLS Nasdaq
- Market Cap
- FOA 272.8M
- CLLS 299.0M
- IPO Year
- FOA N/A
- CLLS 2007
- Fundamental
- Price
- FOA $21.50
- CLLS $3.49
- Analyst Decision
- FOA Buy
- CLLS Buy
- Analyst Count
- FOA 2
- CLLS 1
- Target Price
- FOA $27.50
- CLLS $8.00
- AVG Volume (30 Days)
- FOA 119.3K
- CLLS 186.3K
- Earning Date
- FOA 11-04-2025
- CLLS 11-03-2025
- Dividend Yield
- FOA N/A
- CLLS N/A
- EPS Growth
- FOA N/A
- CLLS N/A
- EPS
- FOA 7.10
- CLLS N/A
- Revenue
- FOA $527,520,999.00
- CLLS $63,438,000.00
- Revenue This Year
- FOA $21.21
- CLLS N/A
- Revenue Next Year
- FOA $10.95
- CLLS $66.76
- P/E Ratio
- FOA $3.06
- CLLS N/A
- Revenue Growth
- FOA 46.94
- CLLS 223.09
- 52 Week Low
- FOA $11.33
- CLLS $1.10
- 52 Week High
- FOA $32.40
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- FOA 38.78
- CLLS 46.96
- Support Level
- FOA $22.38
- CLLS $3.43
- Resistance Level
- FOA $23.03
- CLLS $3.79
- Average True Range (ATR)
- FOA 0.74
- CLLS 0.31
- MACD
- FOA 0.09
- CLLS -0.09
- Stochastic Oscillator
- FOA 16.19
- CLLS 4.60
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.